Compare Ascendis Pharma A/S (ASND) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Marathon Digital Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $255.19 (market cap $16.67B), while Marathon Digital Holdings Inc trades at $9.69 (market cap $3.74B). The key difference: Ascendis Pharma A/S is far larger — about 4.5× Marathon Digital Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | MARA | |
|---|---|---|
Market Cap | $16.67B | $3.74B |
Sector | Health | Technology |
52-Week High | $277.18 | $22.84 |
52-Week Low | $189.74 | $6.73 |
Enterprise Value | $17.04B | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
MARA Holdings trades at $9.675, down 1.2% on the day, with a bearish technical signal and negative earnings trends. The company reported a Q2 2026 net loss of $1.60 per share, missing estimates, while revenue declined to $804 million in 2026. Despite a 50% analyst buy rating and a $16.08 consensus price target, profitability remains challenged with a -429.71% net income margin. Recent news highlights a strategic pivot toward AI digital infrastructure amid Bitcoin mining headwinds.
The outlook is mixed: valuation ratios like P/E of 3.37 suggest potential undervaluation, but persistent losses and high debt-to-asset ratio of 49.43% pose significant risks. Upside depends on successful execution of the AI infrastructure strategy, while downside risks include continued earnings misses and cryptocurrency market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
